Sildenafil Tablet
Product Images NDC 27241-124

7 FDA label images from Ajanta Pharma Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 27241-124). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Sildenafil Structure)

Structure (Sildenafil Structure)
Chemical structure of Sildenafil, illustrating its molecular framework with distinct functional groups and heterocyclic rings.*
FDA Label Image

Figure1 (Sildenafil Fig1)

Figure1 (Sildenafil Fig1)
A dot plot chart showing drug interaction data comparing changes in AUC and Cmax relative to Sildenafil alone. It lists multiple interacting drugs and oral contraceptives on the vertical axis, with a horizontal axis representing change ratios from 0.2 to 13. Each drug has paired points with confidence intervals indicating the magnitude of interaction and recommendations such as no dose adjustment or coadministration not recommended.*
FDA Label Image

Figure2 (Sildenafil Fig2)

Figure2 (Sildenafil Fig2)
A horizontal forest plot chart displaying fold changes and 95% confidence intervals for various interacting drugs on the pharmacokinetics of Sildenafil 20 mg tablet. The chart includes drugs such as Aspirin, Atorvastatin, Bosentan, Doxazosin, Ethinylestradiol, Levonorgestrel, Phenprocoumon, Ritonavir, Saquinavir, and Tolbutamide. Recommendations related to dose adjustments or cautions are listed alongside each drug.*
FDA Label Image

Figure3 (Sildenafil Fig3)

Figure3 (Sildenafil Fig3)
Line graph illustrating change from baseline (in meters) over weeks 4, 8, and 12 in a study comparing placebo and Sildenafil at 20 mg, 40 mg, and 80 mg doses taken three times daily (TID). Data points show increases in the measured parameter over time for Sildenafil doses compared to placebo, with error bars indicating variability.*
FDA Label Image

Figure4 (Sildenafil Fig4)

Figure4 (Sildenafil Fig4)
A forest plot chart illustrating the placebo-corrected change in 6-minute walk distance (in meters) for Sildenafil 20 mg TID versus placebo. The chart compares subgroups based on baseline walk distance, etiology, pulmonary hypertension criteria, gender, age, mean pulmonary artery pressure (PAP), and pulmonary vascular resistance index (PVRI) with confidence intervals shown for each category.*
FDA Label Image

Figure5 (Sildenafil Fig5)

Figure5 (Sildenafil Fig5)
A line graph comparing the percentage of patients without a clinically worsening event over time, from day 0 to 112, between placebo and Sildenafil treatment groups. The x-axis represents days from randomization, while the y-axis shows the percentage without worsening events. Sildenafil shows a higher percentage compared to placebo throughout the period.*
FDA Label Image

20mg (Sildenafil 20mg)

20mg (Sildenafil 20mg)
Label for Sildenafil Tablets, USP 20 mg by Ajanta Pharma USA Inc. The label includes dosage information, storage instructions, a note on child resistance, bar code, and marketing details stating the product is made in India and marketed by Ajanta Pharma USA Inc. The label also shows the product NDC 27241-124-03 and indicates a package count of 90 tablets.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.